Eptaplatin

Description

SKI-2053R was launched in Korea for the treatment of patients with advanced gastric adenocarcinoma. It is a third generation platinum complex alkylating agent with less nephrotoxicity than cisplatin. In in vitro experiments, SKI-2053R was highly active against various cell lines including cisplatinresistant tumor cell lines. In mice implanted with L1210 cells, SKI-2053R showed activity comparable or superior to cisplatin or carboplatin. In mice implanted s.c. with human tumor xenograft KATO III (stomach adenocarcinoma), SKI-2053R achieved growth-inhibition rates comparable with those of cisplatin. General pharmacological studies in animals did not display any severe adverse effects on the different systems at antitumour doses. Pharmacokinetic studies after a single iv administration in rats demonstrated that the compound was extensively and rapidly distributed into all tissues except the CNS. In patients with unresectable or metastatic gastric adenocarcinoma, SKI-2053R was active without significant hematological toxicity. Phase III trials with SKI-2053R are currently ongoing for the treatment of various other cancers including lung, head and neck.

Chemical Properties

White Crystalline Powder

Originator

SK Pharma (Korea)

Uses

A coordination compound for treatment of cervix cancer.

brand name

Sunpla

Pharmaceutical Applications

heptaplatin is further examples of platinum-based agents being used in China and South Korea, respectively. Heptaplatin is used in South Korea to treat gastric cancer. It show the typical side effects such as myelosuppression and mild hepatotoxicity. its success is limited and has not led to approval in the EU or by the FDA.